Pharsight

Finacea patents expiration

FINACEA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6534070 LEO PHARMA AS Composition with azelaic acid
Nov, 2018

(5 years ago)

US6730288 LEO PHARMA AS Mousse composition
Sep, 2019

(4 years ago)

US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Oct, 2023

(7 months ago)

US8900554 LEO PHARMA AS Foamable composition and uses thereof
Oct, 2023

(7 months ago)

US8722021 LEO PHARMA AS Foamable carriers
Oct, 2023

(7 months ago)

US8435498 LEO PHARMA AS Penetrating pharmaceutical foam
Mar, 2024

(3 months ago)

US7700076 LEO PHARMA AS Penetrating pharmaceutical foam
Sep, 2027

(3 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier
Oct, 2027

(3 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Dec, 2027

(3 years from now)

US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof
Feb, 2029

(4 years from now)

Finacea is owned by Leo Pharma As.

Finacea contains Azelaic Acid.

Finacea has a total of 10 drug patents out of which 6 drug patents have expired.

Expired drug patents of Finacea are:

  • US6534070
  • US6730288
  • US10322085
  • US8900554
  • US8722021
  • US8435498

Finacea was authorised for market use on 24 December, 2002.

Finacea is available in aerosol, foam;topical dosage forms.

Finacea can be used as topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

The generics of Finacea are possible to be released after 28 February, 2029.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 24 December, 2002

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage

FINACEA family patents

Family Patents